Zacks Investment Research upgraded shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) from a hold rating to a buy rating in a research report released on Wednesday, July 12th. The firm currently has $1.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
A number of other brokerages also recently issued reports on RGLS. Wedbush reiterated an outperform rating and set a $6.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, March 29th. ValuEngine downgraded Regulus Therapeutics from a sell rating to a strong sell rating in a research note on Friday, June 2nd. BMO Capital Markets restated a hold rating on shares of Regulus Therapeutics in a research note on Monday, May 15th. Finally, Chardan Capital dropped their price target on Regulus Therapeutics from $5.00 to $2.50 and set a buy rating for the company in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Regulus Therapeutics has an average rating of Hold and a consensus price target of $3.58.
Regulus Therapeutics (NASDAQ:RGLS) traded up 2.7815% during midday trading on Wednesday, reaching $0.9201. 357,958 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.29. The firm’s market cap is $95.49 million. Regulus Therapeutics has a 1-year low of $0.85 and a 1-year high of $3.68.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.10. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. Equities research analysts anticipate that Regulus Therapeutics will post ($1.10) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/11/regulus-therapeutics-inc-nasdaqrgls-raised-to-buy-at-zacks-investment-research-updated-updated-updated.html.
In other news, Director William H. Rastetter acquired 274,725 shares of Regulus Therapeutics stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average cost of $0.91 per share, for a total transaction of $249,999.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph P. Hagan purchased 219,780 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average price of $0.91 per share, with a total value of $199,999.80. Following the completion of the transaction, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 549,450 shares of company stock valued at $500,000. 4.80% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Quantitative Investment Management LLC purchased a new stake in Regulus Therapeutics during the second quarter valued at about $103,000. Tudor Investment Corp Et Al bought a new position in Regulus Therapeutics during the fourth quarter valued at approximately $105,000. GSA Capital Partners LLP bought a new position in Regulus Therapeutics during the second quarter valued at approximately $139,000. Teachers Advisors LLC boosted its position in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 9,804 shares during the last quarter. Finally, LMR Partners LLP bought a new position in Regulus Therapeutics during the second quarter valued at approximately $164,000. Institutional investors own 21.09% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.